- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00981058
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (SQUIRE)
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multinational, randomized, multicenter, open-label, Phase III study of 1093 participants (age ≥ 18 years) with histologically- or cytologically-confirmed, stage IV squamous-cell NSCLC, who have received no prior therapy for metastatic disease, will be randomized on a 1:1 basis to receive first-line necitumumab plus chemotherapy consisting of gemcitabine and cisplatin in study Arm A, or gemcitabine-cisplatin chemotherapy alone in study Arm B. Baseline radiographic assessment of disease will be performed within 21 days prior to randomization (first treatment will be administered within 7 days following randomization). Participants will undergo radiographic assessment of disease status (computed tomography or magnetic resonance imaging) every 6 weeks (± 3 days), until there is radiographic documentation of progressive disease (PD). Chemotherapy will continue for a maximum of six cycles in each arm (or until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance or withdrawal of consent); participants in Arm A only will continue to receive necitumumab until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.
After the end-of-study-visit (following PD), follow-up information regarding further anticancer treatment and survival will be collected every 2 months (± 7 days). For participants who discontinue study for reasons other than PD (eg, symptomatic deterioration), information on disease progression will also be collected until PD is documented. Follow-up will continue as long as the participant is alive, or until the end of the trial.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Garran, New South Wales, Australia, 2605
- ImClone Investigational Site
-
Westmead, New South Wales, Australia, 2145
- ImClone Investigational Site
-
Wollongong, New South Wales, Australia, 2500
- ImClone Investigational Site
-
-
Victoria
-
East Bentleigh, Victoria, Australia, 3165
- ImClone Investigational Site
-
Geelong, Victoria, Australia, 3220
- ImClone Investigational Site
-
-
-
-
-
Linz, Austria, 4020
- ImClone Investigational Site
-
Wien, Austria, 1090
- ImClone Investigational Site
-
Wien, Austria, 1130
- ImClone Investigational Site
-
-
-
-
-
Duffel, Belgium, 2570
- ImClone Investigational Site
-
Liege, Belgium, 4000
- ImClone Investigational Site
-
Namur, Belgium, 5000
- ImClone Investigational Site
-
-
-
-
-
Barretos, Brazil, 14784-400
- ImClone Investigational Site
-
Brasilia, Distrito Federal, Brazil, 70710-904
- ImClone Investigational Site
-
Goiania, Brazil, 74884-606
- ImClone Investigational Site
-
Ijui, Brazil, 98700-000
- ImClone Investigational Site
-
Itajai, Brazil, 88301-220
- ImClone Investigational Site
-
Lajeado, Brazil, 95900-000
- ImClone Investigational Site
-
Porto Alegre/RS, Brazil, 90610-000
- ImClone Investigational Site
-
Salvador, Brazil, 40050-410
- ImClone Investigational Site
-
Santo Andre, Brazil, 09090-780
- ImClone Investigational Site
-
Sao Paulo, Brazil, 01224-010
- ImClone Investigational Site
-
São Paulo - SP, Brazil, 01246-000
- ImClone Investigational Site
-
-
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- ImClone Investigational Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6R 3J7
- ImClone Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- ImClone Investigational Site
-
-
-
-
-
Dubrovnik, Croatia, 20000
- ImClone Investigational Site
-
Pula, Croatia, 52100
- ImClone Investigational Site
-
Zagreb, Croatia, 10000
- ImClone Investigational Site
-
-
-
-
-
Brest Cedex, France, 29609
- ImClone Investigational Site
-
Caen, France, 14076
- ImClone Investigational Site
-
Draguignan, France, 83300
- ImClone Investigational Site
-
Grenoble, France, 38043
- ImClone Investigational Site
-
Le Mans, France, 72000
- ImClone Investigational Site
-
Le Mans Cedex, France, 72037
- ImClone Investigational Site
-
Lille, France, 59020
- ImClone Investigational Site
-
Lyon, France, 69373
- ImClone Investigational Site
-
Marseille, France, 13009
- ImClone Investigational Site
-
Paris, France, 75571
- ImClone Investigational Site
-
Paris, France, 75005
- ImClone Investigational Site
-
Paris, France, 75010
- ImClone Investigational Site
-
Paris, France, 75651
- ImClone Investigational Site
-
Rennes, France, 35033
- ImClone Investigational Site
-
Saint-Jean, France, 31240
- ImClone Investigational Site
-
Toulon Armées, France, 83800
- ImClone Investigational Site
-
-
-
-
-
Berlin, Germany, 12200
- ImClone Investigational Site
-
Essen, Germany, 45122
- ImClone Investigational Site
-
Essen, Germany, 45136
- ImClone Investigational Site
-
Frankfurt, Germany, 60487
- ImClone Investigational Site
-
Gauting, Germany, 82131
- ImClone Investigational Site
-
Großhansdorf, Germany, 22927
- ImClone Investigational Site
-
Halle, Germany, 06120
- ImClone Investigational Site
-
Hamburg, Germany, 22087
- ImClone Investigational Site
-
Hamburg, Germany, 21075
- ImClone Investigational Site
-
Heidelberg, Germany, 69126
- ImClone Investigational Site
-
Hemer, Germany, 58675
- ImClone Investigational Site
-
Hofheim, Germany, 65719
- ImClone Investigational Site
-
Karlsruhe, Germany, 76137
- ImClone Investigational Site
-
Lostau, Germany, 39291
- ImClone Investigational Site
-
Löwenstein, Germany, 74245
- ImClone Investigational Site
-
München, Germany, 81675
- ImClone Investigational Site
-
Münster, Germany, 48149
- ImClone Investigational Site
-
Regensburg, Germany, 93042
- ImClone Investigational Site
-
Regensburg, Germany, 93049
- ImClone Investigational Site
-
Ulm, Germany, 89081
- ImClone Investigational Site
-
-
-
-
-
Athens, Greece, 11527
- ImClone Investigational Site
-
Heraklion, Crete, Greece, 71110
- ImClone Investigational Site
-
Patras, Greece, 26500
- ImClone Investigational Site
-
Thessaloniki, Greece, 57010
- ImClone Investigational Site
-
-
-
-
-
Budapest, Hungary, 1125
- ImClone Investigational Site
-
Budapest, Hungary, 1145
- ImClone Investigational Site
-
Deszk, Hungary, 6772
- ImClone Investigational Site
-
Farkasgyepü, Hungary, 8582
- ImClone Investigational Site
-
Mosonmagyaróvár, Hungary, 9200
- ImClone Investigational Site
-
Szombathely, Hungary, 9700
- ImClone Investigational Site
-
Székesfehérvár, Hungary, 8000
- ImClone Investigational Site
-
Törökbálint, Hungary, 2045
- ImClone Investigational Site
-
-
-
-
-
Frosinone, Italy, 03100
- ImClone Investigational Site
-
Genova, Italy, 16132
- ImClone Investigational Site
-
Milano, Italy, 20133
- ImClone Investigational Site
-
Milano, Italy, 20162
- ImClone Investigational Site
-
Monza, Italy, 20900
- ImClone Investigational Site
-
Parma, Italy, 43100
- ImClone Investigational Site
-
Perugia, Italy, 06126
- ImClone Investigational Site
-
-
Lucca
-
Lido di Camaiore, Lucca, Italy, 55041
- ImClone Investigational Site
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33081
- ImClone Investigational Site
-
-
-
-
-
Incheon, Korea, Republic of, 405760
- ImClone Investigational Site
-
Jeonju-si, Korea, Republic of, 561712
- ImClone Investigational Site
-
Seongnam, Korea, Republic of, 463-707
- ImClone Investigational Site
-
Seoul, Korea, Republic of, 120752
- ImClone Investigational Site
-
Seoul, Korea, Republic of, 135710
- ImClone Investigational Site
-
Seoul, Korea, Republic of, 138736
- ImClone Investigational Site
-
Suwon, Korea, Republic of, 442723
- ImClone Investigational Site
-
-
-
-
-
Cebu, Philippines, 6000
- ImClone Investigational Site
-
Cebu City, Philippines, 6000
- ImClone Investigational Site
-
Davao City, Philippines, 8000
- ImClone Investigational Site
-
Makati City, Philippines, 1229
- ImClone Investigational Site
-
Manila, Philippines, 1000
- ImClone Investigational Site
-
Quezon City, Philippines, 1102
- ImClone Investigational Site
-
Quezon City, Philippines, 1000
- ImClone Investigational Site
-
-
-
-
-
Olsztyn, Poland, 10357
- ImClone Investigational Site
-
Otwock, Poland, 05-400
- ImClone Investigational Site
-
Poznan, Poland, 60-569
- ImClone Investigational Site
-
Radom, Poland, 26-617
- ImClone Investigational Site
-
Rzeszow, Poland, 35-055
- ImClone Investigational Site
-
Szczecin, Poland, 70-891
- ImClone Investigational Site
-
Torun, Poland, 87-100
- ImClone Investigational Site
-
Wroclaw, Poland, 53-439
- ImClone Investigational Site
-
-
-
-
-
Coimbra, Portugal, 3041-801
- ImClone Investigational Site
-
Lisboa, Portugal, 1649-035
- ImClone Investigational Site
-
Lisboa, Portugal, 1099-023
- ImClone Investigational Site
-
Porto, Portugal, 4200-072
- ImClone Investigational Site
-
-
-
-
-
Brasov, Romania, 500366
- ImClone Investigational Site
-
Bucharest, Romania, 022328
- ImClone Investigational Site
-
Bucharest, Romania, 030171
- ImClone Investigational Site
-
Cluj-Napoca, Romania, 400015
- ImClone Investigational Site
-
Craiova, Dolj, Romania, 200385
- ImClone Investigational Site
-
Iasi, Romania, 700106
- ImClone Investigational Site
-
Piatra Neamt, Romania, 610136
- ImClone Investigational Site
-
Sibiu, Romania, 550245
- ImClone Investigational Site
-
-
-
-
-
Ivanovo, Russian Federation, 153013
- ImClone Investigational Site
-
Kirov, Russian Federation, 610021
- ImClone Investigational Site
-
Krasnodar, Russian Federation, 350040
- ImClone Investigational Site
-
Moscow, Russian Federation, 117997
- ImClone Investigational Site
-
Omsk, Russian Federation, 644013
- ImClone Investigational Site
-
Smolensk, Russian Federation, 214000
- ImClone Investigational Site
-
St. Petersburg, Russian Federation, 197022
- ImClone Investigational Site
-
St. Petersburg, Russian Federation, 194044
- ImClone Investigational Site
-
St. Petersburg, Russian Federation, 198255
- ImClone Investigational Site
-
St. Petersburg, Russian Federation, 194291
- ImClone Investigational Site
-
Ufa, Russian Federation, 450054
- ImClone Investigational Site
-
Yaroslavl, Russian Federation, 150054
- ImClone Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- ImClone Investigational Site
-
Kragujevac, Serbia, 34000
- ImClone Investigational Site
-
Nis, Serbia, 18204
- ImClone Investigational Site
-
Sremska Kamenica, Serbia, 21204
- ImClone Investigational Site
-
-
-
-
-
Singapore, Singapore, 308433
- ImClone Investigational Site
-
-
-
-
-
Bratislava, Slovakia, 826 06
- ImClone Investigational Site
-
Nitra, Slovakia, 949 88
- ImClone Investigational Site
-
Poprad, Slovakia, 058 01
- ImClone Investigational Site
-
-
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9301
- ImClone Investigational Site
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0002
- ImClone Investigational Site
-
-
Kwazulu-Natal
-
Durban, Kwazulu-Natal, South Africa, 4091
- ImClone Investigational Site
-
-
-
-
-
Barcelona, Spain, 08036
- ImClone Investigational Site
-
L'Hospitalet de Llobregat, Spain, 08908
- ImClone Investigational Site
-
Madrid, Spain, 28040
- ImClone Investigational Site
-
-
Andalucía
-
Sevilla, Andalucía, Spain, 41013
- ImClone Investigational Site
-
-
Castilla Y Leon
-
Avila, Castilla Y Leon, Spain, 05004
- ImClone Investigational Site
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08035
- ImClone Investigational Site
-
Barcelona, Cataluña, Spain, 08041
- ImClone Investigational Site
-
Terrassa, Cataluña, Spain, 08221
- ImClone Investigational Site
-
-
Communidad De Madrid
-
Madrid, Communidad De Madrid, Spain, 28041
- ImClone Investigational Site
-
Madrid, Communidad De Madrid, Spain, 28050
- ImClone Investigational Site
-
Majadahonda, Communidad De Madrid, Spain, 28222
- ImClone Investigational Site
-
-
-
-
-
Taichung, Taiwan, 40447
- ImClone Investigational Site
-
Taichung, Taiwan, 40705
- ImClone Investigational Site
-
-
-
-
-
Chiang Mai, Thailand, 50002
- ImClone Investigational Site
-
Songkhla, Thailand, 90110
- ImClone Investigational Site
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- ImClone Investigational Site
-
Bournemouth, United Kingdom, BH7 7DW
- ImClone Investigational Site
-
Dundee, United Kingdom, DD1 9SY
- ImClone Investigational Site
-
Edinburgh, United Kingdom, EH4 2XU
- ImClone Investigational Site
-
Guildford, United Kingdom, GU2 7XX
- ImClone Investigational Site
-
Liverpool, United Kingdom, L14 3PE
- ImClone Investigational Site
-
London, United Kingdom, SW10 9NH
- ImClone Investigational Site
-
Manchester, United Kingdom, M20 4BX
- ImClone Investigational Site
-
Manchester, United Kingdom, M23 9LT
- ImClone Investigational Site
-
Preston, United Kingdom, PR2 9HT
- ImClone Investigational Site
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- ImClone Investigational Site
-
-
Arkansas
-
Fayetteville, Arkansas, United States, 72703
- ImClone Investigational Site
-
-
California
-
Sacramento, California, United States, 95816
- ImClone Investigational Site
-
-
Illinois
-
Galesburg, Illinois, United States, 61401
- ImClone Investigational Site
-
-
Indiana
-
Goshen, Indiana, United States, 46526
- ImClone Investigational Site
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- ImClone Investigational Site
-
-
Kentucky
-
Hazard, Kentucky, United States, 41701
- ImClone Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- ImClone Investigational Site
-
-
Missouri
-
Jefferson City, Missouri, United States, 65109
- ImClone Investigational Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- ImClone Investigational Site
-
-
New York
-
New York, New York, United States, 10065
- ImClone Investigational Site
-
-
Ohio
-
Akron, Ohio, United States, 44304
- ImClone Investigational Site
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
- ImClone Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- ImClone Investigational Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- ImClone Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has histologically or cytologically confirmed squamous NSCLC
- Has Stage IV disease at the time of study entry
- Measurable or nonmeasurable disease at the time of study entry as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) (participants with only truly nonmeasurable disease are not eligible)
- Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)
- Has adequate hepatic function
- Has adequate renal function
- Has adequate hematologic function
- If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method (failure rate < 1%) during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method)
- If male, the participant is surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period
- Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization
- Has archived tumor tissue available for analysis of EGFR and KRAS mutation status (by PCR) and EGFR gene copy number (by FISH); minimum of four slides, paraffin-embedded tissue, required
Exclusion Criteria:
- Has nonsquamous NSCLC (adenocarcinoma/large cell or other)
- Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor
- Has received previous chemotherapy for advanced NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization)
- Has undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization
- Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)
- Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible
- Has superior vena cava syndrome contraindicating hydration
- Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure
- Has experienced myocardial infarction within 6 months prior to randomization
- Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus
- Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder
- Has any National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0 Grade ≥ 2 peripheral neuropathy
- Has significant third space fluid retention, requiring repeated drainage
- Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the participant's ability to complete the study or sign an informed consent document
- Has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab (IMC-11F8), or any other contraindication to one of the administered treatments
- Is pregnant or breastfeeding
- Has a known history of drug abuse
- Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Necitumumab + Gemcitabine + Cisplatin
|
800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle. Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Other Names:
1250 mg/m2 on Days 1 and 8 of every 3 week cycle. Continues for a maximum of six cycles.
Other Names:
75 mg/m2 IV on Day 1 of every 3 week cycle. Continues for a maximum of six cycles. |
Active Comparator: Gemcitabine + Cisplatin
|
1250 mg/m2 on Days 1 and 8 of every 3 week cycle. Continues for a maximum of six cycles.
Other Names:
75 mg/m2 IV on Day 1 of every 3 week cycle. Continues for a maximum of six cycles. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival Time (OS)
Time Frame: Randomization to Death from Any Cause (Up to 31 Months)
|
Overall survival is defined as the time from randomization to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
OS was estimated by the Kaplan-Meier method.
|
Randomization to Death from Any Cause (Up to 31 Months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)
|
PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause.
Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions.
Participants who die without a reported prior progression were considered to have progressed on the day of their death.
Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment.
If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization.
If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.
|
Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)
|
Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])
Time Frame: Baseline to Measured Progressive Disease (Up to 31 Months)
|
ORR is confirmed best overall tumor response of CR or PR.
According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions.
PR defined as a >=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100.
|
Baseline to Measured Progressive Disease (Up to 31 Months)
|
Time to Treatment Failure (TTF)
Time Frame: Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)
|
TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy.
Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal.
Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.
|
Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)
|
Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)
Time Frame: Baseline, Cycle 6 (Cycle = 3 Weeks)
|
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument.
The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems).
These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm.
The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
|
Baseline, Cycle 6 (Cycle = 3 Weeks)
|
Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)
Time Frame: Baseline, Cycle 6 (Cycle = 3 Weeks)
|
The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life).
Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines.
A higher score for any item represented a higher level of symptoms/problems.
Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome).
The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items.
ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.
|
Baseline, Cycle 6 (Cycle = 3 Weeks)
|
Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)
Time Frame: 31 Months
|
EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells.
IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of <200 and participants with a high EGFR expression defined by a H-score of cutoff value of >=200.
|
31 Months
|
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab
Time Frame: Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months
|
Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months
|
|
Number of Participants With a Serum Anti-Necitumumab Antibody Assessment
Time Frame: Baseline through 31 Months
|
A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.
|
Baseline through 31 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
General Publications
- Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafranski W, Ramlau R, Balint B, Molinier O, Depenbrock H, Nanda S, Paz-Ares L, Thatcher N. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Mar;19(2):130-138.e2. doi: 10.1016/j.cllc.2017.10.004. Epub 2017 Oct 13.
- Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9. doi: 10.1093/annonc/mdw214. Epub 2016 May 20.
- Reck M, Socinski MA, Luft A, Szczesna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002. Epub 2016 Mar 12.
- Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Balint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Necitumumab
- Gemcitabine
Other Study ID Numbers
- 13909
- CP11-0806 (Other Identifier: ImClone Systems)
- I4X-IE-JFCC (Other Identifier: Eli Lilly and Company)
- 2009-013838-25 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Necitumumab
-
Eli Lilly and CompanyCompletedSolid TumorsNetherlands
-
Eli Lilly and CompanyCompletedSolid TumorsUnited States
-
Eli Lilly and CompanyCompletedCarcinoma, Non-Small-Cell Lung | Neoplasm MetastasisSpain, Belgium, France
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCCompletedStage IV Non-Small Cell Lung CancerSpain, United States, France, Japan
-
Eli Lilly and CompanySCRI Development Innovations, LLCTerminatedNon-small Cell Lung Cancer MetastaticUnited States
-
Glycotope GmbHCompletedSolid Tumor, AdultGermany, Italy, Spain
-
Eli Lilly and CompanyCompletedMetastatic Colorectal CancerSpain, Belgium
-
Eli Lilly and CompanyParexelCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedNon-Small Cell Lung CarcinomaUnited States
-
Montefiore Medical CenterEli Lilly and CompanyTerminatedSquamous Cell Lung CancerUnited States